https://www.selleckchem.com/pr....oducts/lomerizine-hc
To describe use of bisphosphonates in newly diagnosed multiple myeloma patients in Denmark. Using data from the Danish National Multiple Myeloma Registry, we conducted a population-based cohort study. Among patients newly diagnosed with multiple myeloma from 2005 to 2015, we examined use of bisphosphonates at first- and at progression/second-line anti-myeloma treatment overall, by patient characteristics, and myeloma complications. Of 2947 patients starting first-line anti-myeloma treatment, 2207 patients (74.9%) received bisphos
Aimer
Commentaire
Partagez
